The head of pharma group Novartis has warned that the US government’s reform of drug pricing risks damaging public health as drugmakers have already begun to cut investment in pills for the elderly.
製藥集團諾華(Novartis)執行長萬思瀚(Vas Narasimhan)警告稱，美國政府對藥品定價的改革可能會損害公衆健康，因爲製藥商已經開始削減對老年人藥物的投資。
您已閱讀6%（285字），剩餘94%（4796字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。